Journal: Acta Pharmaceutica Sinica. B

Article Title: Rhizoma Drynariae-derived nanovesicles reverse osteoporosis by potentiating osteogenic differentiation of human bone marrow mesenchymal stem cells via targeting ER α signaling

doi: 10.1016/j.apsb.2024.02.005

Figure Lengend Snippet: Schematic illustration of RDNVs reverse osteoporosis by potentiating osteogenic differentiation of hBMSCs via targeting estrogen receptor α (ER α ) signaling. RDNVs, a natural product isolated from fresh Rhizoma Drynariae root juice by differential ultracentrifugation, exhibited potent bone tissue-targeting activity and anti-osteoporosis efficacy in an ovariectomized mouse model. RDNVs, effectively internalized by hBMSCs, enhanced proliferation and ER α expression levels of hBMSC, and promoted osteogenic differentiation and bone formation. Mechanistically, via the ER α signaling pathway, RDNVs facilitated mRNA and protein expression of bone morphogenetic protein 2 and runt-related transcription factor 2 in hBMSCs, which are involved in regulating osteogenic differentiation. Further analysis revealed that naringin, existing in RDNVs, was the active component targeting ER α in the osteogenic effect.

Article Snippet: Rabbit polyclonal antibodies against BMP2 ([EPR24209-61] (ab284387)) and RUNX2 ([EPR22858-106] (ab236639)) were purchased from Abcam (Cambridge, MA, USA).

Techniques: Isolation, Activity Assay, Expressing